Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 342,868 trials in your specialties ()
View trials across your selected specialties

Vitamin E Supplementation in Burn Patients

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Burn Injury
View Full Trial
INTERVENTION

Drug: dl-alpha-tocopheryl acetate

Eligibility
  • Ages: 6 to 85 Months (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Shriners Hospitals for Children, Galveston, Texas, United States

Brief Summary

Burned patients because of their increased oxidative stress have severely depleted vitamin E, which is a dietary antioxidant. Oxidative stress is responsible for much of the pathophysiology seen in burned patients, which leads to acute and chronic morbidity and mortality, in addition to a decrease in their quality of life. Oral vitamin E will be used to reverse the oxidative stress of burn injury and, in the process, decrease the secondary consequences of thermal trauma. This proposal will demonstrate the benefit of maintaining adequate vitamin E status.

Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

  • Status
    Not yet recruiting
  • Phase
    Phase 4
  • Condition
    Leukemia
View Full Trial
INTERVENTION

Drug: Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd), Drug: Cytarabine(Actavis Italy S.p.A), Drug: Fludarabine (Bayer), Drug: granulocyte colony-stimulating factor (KirinKunpeng), Drug: rabbit ATG(Sanofi/Genzyme)

Eligibility
  • Ages: 12 to 65 Years (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

The purpose of this study is to determine the safety and efficacy of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor) Conditioning Regimen in Patients with Relapsed/refractory Acute Leukemia undergoing allogeneic peripheral blood stem cell transplantation.

Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Malaria
View Full Trial
INTERVENTION

Biological: Plasmodium falciparum sporozoite (PfSPZ)

Eligibility
  • Ages: 18 to 45 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

KEMRI Wellcome Trust Research Programme, Kilifi, Coast, Kenya

Brief Summary

The investigators wish to understand how resistance to malaria develops and how this affects the growth rate of malaria in individuals who have past exposure to malaria.

Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma

  • Status
    Not yet recruiting
  • Phase
    Phase 4
  • Condition
    Hepatitis B, Carcinoma, Hepatocellular
View Full Trial
INTERVENTION

Drug: Vitamin D3

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

The purpose of this study is to determine whether vitamin D is effective in the prevention of hepatocellular carcinoma in those patients with chronic hepatitis B.

Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Thermal Injury, Deep Partial-Thickness Burn, Full-Thickness Burn
View Full Trial
INTERVENTION

Drug: Autologous Engineered Skin Substitute, Drug: Split-Thickness Autograft (AG)

Eligibility
  • Ages: 18 to 40 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Arizona Burn Center, Pheonix, Arizona, United States

Brief Summary

The purpose of this research study is to test how well the investigational treatment, Engineered Skin Substitutes (ESS-W), works for covering and treating burn wounds. The areas of the body that are treated with ESS-W will be compared to similar areas treated with the patient's own skin (split-thickness skin autograft (AG)). A skin autograft (AG) will be performed by taking healthy skin from one area of the body and placing it on the burned area.

Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Radiation of Neurocranial Region
View Full Trial
INTERVENTION

Radiation: Radiation according to indication with hippocampal sparing, Radiation: Radiation according to indication without hippocampal protection

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Universitätsklinikum Erlangen, Erlangen, Germany

Brief Summary

This randomized trial examines possible enhancements in live quality and neurocognitive functions in patients after radiotherapy of the neurocranial area with hippocampal sparing. Although the hippocampus has a crucial role in regard to neurocognition and memory, hippocampal region has been relatively disregarded in radiotherapy of neurocranium so far. Brain metastases in the hippocampal region are very rare and an infiltration of the hippocampus by meningioma or by pituitary adenoma just occurs when volume of the tumor is very high. This study aims to reduce the radiation dose in the hippocampal region to improve the quality of live and neurocognitive functions in patients without degrading prognosis or increasing probability of brain metastases in hippocampal region. Primary endpoint of the trial is quality of live and neurocognitive functions in patients after radiation of neurocranial region with hippocampal sparing compared with conventional radiotherapy of the neurocranial region without hippocampal sparing. Secondary endpoints are cerebral recurrence rate in hippocampal region and overall survival. It is planned to include a total number of 150 patients.

Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major

  • Status
    Recruiting
  • Phase
    Phase 4
  • Condition
    Thalassemia Major
View Full Trial
INTERVENTION

Drug: Busulfan, Drug: Cyclophosphamide, Drug: Fludarabine, Drug: Mycophenolate mofetil, Drug: Tacrolimus, Drug: Methotrexate, Drug: Thymoglobulin, Drug: Basiliximab

Eligibility
  • Ages: 2 to 18 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Brief Summary

The purpose of the study is to assess the safety and efficacy of haploidentical hematopoietic stem cell transplantation for patients with thalassemia major.

Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy

  • Status
    Not yet recruiting
  • Phase
    Phase 3
  • Condition
    Hypoxic-Ischemic Encephalopathy
View Full Trial
INTERVENTION

Drug: normal saline, Drug: Erythropoietin

Eligibility
  • Ages: up to 24 / (18 to 64 years)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

Perinatal hypoxic-ischaemic encephalopathy occurs in one to three infants per 1000 term births, and up to 12 000 infants are affected each year in the united state of America. Hypoxic ischemic encephalopathy is not preventable in most cases, and therapies are limited. Hypothermia improves outcomes and is the current standard of care. Yet clinical trials suggest that 44% to 53% of infants who receive hypothermia will die or suffer moderate to severe neurological disability. Therefore, novel neuroprotective therapies are urgently needed to further reduce the rate and severity of neurodevelopmental disabilities resulting from hypoxic ischemic encephalopathy. Erythropoietin is a novel neuroprotective agent, with remarkable neuroprotective and neuroregenerative effects in animals. Rodent and primate models of neonatal brain injury support the safety and efficacy of multiple erythropoietin doses for improving histological and functional outcomes after hypoxia-ischaemia.

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Carotid Artery Stenosis, Strokes
View Full Trial
INTERVENTION

Drug: Statin, Drug: Atorvastatin, Other: Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Valley Hospital, Ridgewood, New Jersey, United States

Brief Summary

The investigators hypothesize that pre-operative statin use is neuroprotective at maximal doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin doses for two weeks (12-18 days) prior to CEA using change in performance on a battery neuropsychometric tests as outcome measure. Study will recruit patients based on their preexisting statin regimen. The investigators hypothesize that in asymptomatic CEA patients: 1) Pre-operative statin use is neuroprotective against early cognitive dysfunction (eCD) and lowers the risk of early mortality. 2) Maximal doses may be essential in achieving optimal neuroprotection against eCD.

A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Dwarfism
View Full Trial
INTERVENTION

Drug: PEG-somatropin

Eligibility
  • Ages: 4 to 9 Years (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Department of Pediatrics of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Wuhan, Hubei, China

Brief Summary

After the first stage (52 weeks) of Phase II clinical trial, Pegylated recombinant human growth hormone (PEG-rhGH) injection of appropriate dose in compliance with ISS clinical treatment strategy is used to treat children with ISS (Idiopathic Short Stature). The long-term efficacy and safety of the investigational product are evaluated, which can provide more scientific and reliable medication guidance information for clinical diagnosis and treatment.